Interferon beta-1a
- Generic Name
- Interferon beta-1a
- Brand Names
- Avonex, Rebif
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 145258-61-3
- Unique Ingredient Identifier
- XRO4566Q4R
- Background
Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta.
- Indication
For treatment of relapsing/remitting multiple sclerosis, also for condyloma acuminatum
- Associated Conditions
- Relapsing Multiple Sclerosis (RMS)
- Associated Therapies
- -
How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose
- Conditions
- Interventions
- First Posted Date
- 2007-12-14
- Last Posted Date
- 2008-09-04
- Lead Sponsor
- Biogen
- Target Recruit Count
- 19
- Registration Number
- NCT00574041
- Locations
- 🇦🇺
Coordinating Research Site, Malvern, Victoria, Australia
Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a?
- Conditions
- Interventions
- First Posted Date
- 2007-09-24
- Last Posted Date
- 2007-12-13
- Lead Sponsor
- Biogen
- Target Recruit Count
- 284
- Registration Number
- NCT00534261
- Locations
- 🇬🇧
Coordinating Research Site, Glasgow, Scotland, United Kingdom
Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta
- Conditions
- Interventions
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2013-09-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 20
- Registration Number
- NCT00493116
- Locations
- 🇳🇿
Research Site, Hamilton, New Zealand
🇦🇺Coordinating Research Site, NSW, Australia
Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies
- Conditions
- Interventions
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2008-01-30
- Lead Sponsor
- Biogen
- Target Recruit Count
- 14
- Registration Number
- NCT00492466
- Locations
- 🇫🇮
Coordinating Research Site, Turku, Finland
Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2010-10-15
- Lead Sponsor
- Biogen
- Target Recruit Count
- 380
- Registration Number
- NCT00492765
- Locations
- 🇩🇰
Coordinating Research Site, Copenhagen, Denmark
Safety and Efficacy of Treatment With Interferon Beta-1a Rebif® in Patients With Crohn's Disease
- Conditions
- First Posted Date
- 2006-03-17
- Last Posted Date
- 2013-08-06
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 192
- Registration Number
- NCT00304252
- Locations
- 🇬🇧
Medical Information Office, Feltham, United Kingdom
A Multicenter Phase 3 Study of Interferon-beta-1a for the Treatment of Chronic Hepatitis C in Asian Subjects
- Conditions
- Interventions
- First Posted Date
- 2005-11-07
- Last Posted Date
- 2013-08-06
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 257
- Registration Number
- NCT00249860
Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx
- Conditions
- Interventions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2014-04-03
- Lead Sponsor
- Fred Lublin
- Target Recruit Count
- 1008
- Registration Number
- NCT00211887
- Locations
- 🇺🇸
MS Center of Atlanta, Atlanta, Georgia, United States
🇺🇸Shepherd Center, Atlanta, Georgia, United States
🇺🇸Northwest University, Chicago, Illinois, United States
Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
- Conditions
- First Posted Date
- 2004-12-16
- Last Posted Date
- 2010-03-05
- Lead Sponsor
- Biogen
- Target Recruit Count
- 67
- Registration Number
- NCT00099489
- Locations
- 🇺🇸
Phoenix Neurological Associates, Ltd., Phoenix, Arizona, United States
🇬🇧Guy's Hospital/Dept. of Neuroimmunology, London, United Kingdom
🇺🇸University of Texas Southwestern, Dallas, Texas, United States
Safety Study of Interferon Beta 1a to for Acute Stroke
- Conditions
- First Posted Date
- 2004-11-22
- Last Posted Date
- 2017-07-02
- Target Recruit Count
- 60
- Registration Number
- NCT00097318
- Locations
- 🇺🇸
Washington Hospital Center, Washington, D.C., District of Columbia, United States
🇺🇸Suburban Hospital, Bethesda, Maryland, United States
🇺🇸National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.